Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8734659 | Revista Brasileira de Hematologia e Hemoterapia | 2017 | 9 Pages |
Abstract
Splenic marginal zone lymphoma (SMZL) is a low-grade B-cell non-Hodgkin's lymphoma characterized by massive splenomegaly, moderate lymphocytosis with or without villous lymphocytes, rare involvement of peripheral lymph nodes and indolent clinical course. As a rare disease, with no randomized prospective trials, there is no standard of care for SMZL so far. Splenectomy has been done for many years as an attempt to control disease, but nowadays it has not been encouraged as first line because of new advances in therapy as rituximab, that are as effective with minimal toxicity. Facing these controversies, this review highlights advances in the literature regarding diagnosis, prognostic factors, treatment indications and therapeutic options.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
Tayse Silva dos Santos, Renato Sampaio Tavares, Danielle Leão Cordeiro de Farias,